Overview

Corticosteroid Therapy for Severe Community-Acquired Pneumonia

Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (PSI 4-5). The hypothesis of the study is that methylprednisolone can decrease the mortality of severe CAP without any significant side effects,with reduction of the time to clinical stability and failure rate of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Affiliated Hospital of Hebei University
Affiliated hospital of Taishan medical university
Cangzhou Central Hospital
Cangzhou People's Hospital
First Affiliated Hospital of Wenzhou Medical University
Jinhua Central Hospital
Nantong University
Navy general hospital PLA China
Northern Jiangsu Province People's Hospital
Taishan Medical University Affiliated Hospital
The First Affiliated Hospital of Anhui Medical University
The Second Hospital of Hebei Medical University
Tianjin Medical University General Hospital
Tianjin Third Central Hospital
Zhejiang University
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate